People who are obtaining cyclosporine, tacrolimus or other agents to avoid graft-vs .-host condition post bone marrow transplant are certainly not eligible for this trial Experimental: Dose expansion_sub-population 2_higher dose of niraparib MTDs and/or candidate RP2Ds for elimusertib employed together with niraparib at an increased fixed dose. Every one of https://oligomycina65432.alltdesign.com/getting-my-molnupiravir-to-work-46654526